secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-270019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS
--------------------------------------------------------------------------------

- Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.
- FY2025 revenue guidance narrowed to $36M-$38M; combined 2026 with IRRAS expected $54M-$60M.
- Signed agreement to acquire IRRAS Holdings; no purchase price disclosed.
- New CAL preclinical facility operational; FDA 510(k) clearance for 1.5T PRISM Laser Therapy.
- Active biopharma partners >60; plan to activate 35-40 specialized centers for cell/gene therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000119312525270019/0001193125-25-270019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000119312525270019/clpt-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-270019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer